Milojevic, Bogomir (36990126400)Bogomir (36990126400)MilojevicDjokic, Milan (15019194000)Milan (15019194000)DjokicSipetic-Grujicic, Sandra (6701802171)Sandra (6701802171)Sipetic-GrujicicMilenkovic-Petronic, Dragica (24923372100)Dragica (24923372100)Milenkovic-PetronicVuksanovic, Aleksandar (6602999284)Aleksandar (6602999284)VuksanovicBumbasirevic, Uros (36990205400)Uros (36990205400)BumbasirevicVukovic, Ivan (23500559400)Ivan (23500559400)VukovicDragicevic, Dejan (6506794751)Dejan (6506794751)DragicevicTulic, Cane (6602213245)Cane (6602213245)Tulic2025-06-122025-06-122012https://doi.org/10.1111/j.1464-410X.2011.10461.xhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-84858450920&doi=10.1111%2fj.1464-410X.2011.10461.x&partnerID=40&md5=f228e0149bf4b78d3a0c3b9505a2d3behttps://remedy.med.bg.ac.rs/handle/123456789/9721Objective To identify the impact of tumour location on the disease recurrence and survival of patients who were treated surgically for upper urinary tract transitional cell carcinoma (UUT-TCC). Patients and Methods A single-centre series of 189 consecutive patients who were treated surgically for UUT-TCC between January 1999 and December 2009 was evaluated. Patients who had previously undergone radical cystectomy, preoperative chemotherapy or contralateral UUT-TCC were excluded. In all, 133 patients were available for evaluation. Tumour location was categorized as renal pelvis or ureter based on the location of the dominant tumour. Recurrence-free probabilities and cancer-specific survival were estimated using the Kaplan-Meier method and Cox regression analyses. Results The 5-year recurrence-free and cancer-specific survival estimates for the cohort in the present study were 66% and 62%, respectively. The 5-year bladder-only recurrence-free probability was 76%. Using multivariate analysis, only pT classification (hazard ratio, HR, 2.46; P= 0.04) and demographic characteristics (HR, 2.86 for areas of Balkan endemic nephropathy, vs non-Balkan endemic nephropathy areas; 95% confidence interval, 1.37-5.98; P= 0.005) were associated with disease recurrence Tumour location was not associated with disease recurrence in any of the analyses. There was no difference in cancer-specific survival between renal pelvis and ureteral tumours (P= 0.476). Using multivariate analysis, pT classification (HR, 8.04; P= 0.001) and lymph node status (HR, 4.73; P= 0.01) were the only independent predictors associated with a worse cancer-specific survival. Conclusions Tumour location is unable to predict outcomes in a single-centre series of consecutive patients who were treated with radical nephroureterectomy for UUT-TCC. © 2011 The Authors. BJU International.recurrencerenal pelvissurvivaltransitional cell carcinomaureter